Showing results (61-70 of 169) with videos related to

Sort By:
Pageof 17
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trialElisabeth Sophie Bergen, Clémence Canton, Mathieu Boulin, et al.
Clinical Pharmacokinetics|October 10, 2007
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration scheduleMarie-Christine Etienne-Grimaldi, Eric François, Jean-Michel Cardot, et al.
Bulletin Du Cancer|July 1, 2014
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]Marie Wislez, David Malka, Jaafar Bennouna, et al.
Molecular Cancer Therapeutics|May 20, 2017
Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor ErlotinibJudith Raimbourg, Marie-Pierre Joalland, Mathilde Cabart, et al.
Clinical Lung Cancer|June 28, 2011
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trialCesare Gridelli, Jaafar Bennouna, Javier de Castro, et al.
Clinical Colorectal Cancer|November 28, 2021
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II StudyAurelie Bertaut, Yann Touchefeu, Julie Blanc, et al.
International Journal of Cancer|May 18, 2010
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancerMichel Ducreux, Jaafar Bennouna, Mohamed Hebbar, et al.
Cancer Research|January 10, 2002
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cellsHassane M Zarour, Bernard Maillere, Vladimir Brusic, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2010
Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumorsJaafar Bennouna, Vincent Levy, Hélène Sicard, et al.
Pageof 17